2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2/3
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
543
Neoplasms
449
Carcinoma, Non-Small-Cell Lung
410
Prostatic Neoplasms
334
Colorectal Neoplasms
315
Lung Neoplasms
261
Multiple Myeloma
229
Neoplasm Metastasis
190
Pancreatic Neoplasms
186
Leukemia, Myeloid, Acute
183
Ovarian Neoplasms
178
Melanoma
147
Squamous Cell Carcinoma of Head and Neck
140
Carcinoma, Hepatocellular
116
Recurrence
115
Head and Neck Neoplasms
114
Carcinoma, Renal Cell
112
Lymphoma
111
Stomach Neoplasms
110
Endometrial Neoplasms
110
Precursor Cell Lymphoblastic Leukemia-Lymphoma
109
Glioblastoma
108
Brain Neoplasms
106
Lymphoma, Non-Hodgkin
105
Uterine Cervical Neoplasms
100
Triple Negative Breast Neoplasms
97
Urinary Bladder Neoplasms
95
Hematologic Neoplasms
91
Leukemia, Lymphocytic, Chronic, B-Cell
88
Lymphoma, Large B-Cell, Diffuse
84
Interventions
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Camurati-Engelmann Syndrome
×
30 days
×
Clear all
NCT06788990
2026-06-02
FORTIFI-HN01
Bicara Therapeutics
Phase 2/3
Recruiting
650 enrolled
NCT05209776
2026-06-01
LI-ARVC
University Hospital, Toulouse
Phase NA
Recruiting
80 enrolled